Bempikibart showed a 35.3% mean reduction in SALT score at 36 weeks in severe alopecia areata, with 40% of patients achieving significant hair regrowth and a favorable safety profile. Early durability and robust PK/ADA data support further development.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.